

TO: Don Zhang

LSUAM | Col of HSS | Psychology | CC00124

FROM: Alex Cohen

Chairman, Institutional Review Board

**DATE:** 06-Feb-2023 **RE:** IRBAM-23-0045

TITLE: Risk Perceptions of Constructive Deviance Behaviors

**SUBMISSION TYPE:** Initial Application

Review Type: Exempt
Risk Factor: Minimal
Review Date: 06-Feb-2023
Status: Approved
Approval Date: 06-Feb-2023
Approval Expiration Date: 05-Feb-2026

**Exempt Category:** 2a **Requesting Waiver of Informed Consent:** Yes

**Re-review frequency:** Three Years

Number of subjects approved: 1200

LSU Proposal Number:

By: Alex Cohen, Chairman

## Continuing approval is CONDITIONAL on:

1. Adherence to the approved protocol, familiarity with, and adherence to the ethical standards of the Belmont Report, and LSU's Assurance of Compliance with DHHS regulations for the protection of human subjects\*

- 2. Prior approval of a change in protocol, including revision of the consent documents or an increase in the number of subjects over that approved.
- 3. Obtaining renewed approval (or submittal of a termination report), prior to the approval expiration date, upon request by the IRB office (irrespective of when the project actually begins); notification of project termination.
- 4. Retention of documentation of informed consent and study records for at least 3 years after the study ends.
- 5. Continuing attention to the physical and psychological well-being and informed consent of the individual participants, including notification of new information that might affect consent.
- 6. A prompt report to the IRB of any adverse event affecting a participant potentially arising from the study.
- 7. Notification of the IRB of a serious compliance failure.
- 8. SPECIAL NOTE: When emailing more than one recipient, make sure you use bcc. Approvals will automatically be closed by the IRB on the expiration date unless the PI requests a continuation.

<sup>\*</sup> All investigators and support staff have access to copies of the Belmont Report, LSU's Assurance with DHHS, DHHS (45 CFR 46) and FDA regulations governing use of human subjects, and other relevant documents in print in this office or on our World Wide Web site at <a href="http://www.lsu.edu/research">http://www.lsu.edu/research</a>